Enhancer of Zeste homolog 2 (EZH2) is the methyltransferase enzyme responsible for trimethylating lysine 27 on histone H3 to produce H3K27Me3. EZH2 is a polycomb group protein that is an essential epigenetic regulator that is often found deregulated in a wide variety of malignant cancer types. Using a KMT/EZH2 antibody, researchers have shown that EZH2 is a key regulator in B cell progenitor cells that uses a novel mechanism of IgH rearrangement control not previously known1. Further KMT/EZH2 antibody studies showed that the phosphorylation of EZH2 by the protein kinase Akt suppresses EZH2 methyltransferase activity, resulting in a decrease in H3K27Me3 levels, and concomitant derepression of silenced genes2.
-Immunohistochemistry-Paraffin-NBP1-96082-img0004.jpg "Immunohistochemistry-Paraffin: KMT6/EZH2")
DNA microarray analysis of human glioma samples with a KMT/EZH2 antibody showed clear differences in expression profiles that were confirmed with real-time PCR3. There are several potential EZH2 pathway and downstream cascade targets that have been heavily implicated in cancer progression, thus there are several candidates that could serve as therapeutic targets for the suppression of cancer progression and recurrence4. Interestingly, Hayashi, et al. are using another approach and developing novel synthetic peptides capable of stimulating in vitro T-cell responses for immunotherapy in lung cancer patients, and validating their expression profiles with a KMT/EZH2 antibody5.
Novus Biologicals offers EZH2 reagents for your research needs including:
